Patients with type 2 diabetes who use empagliflozin or sodium-glucose cotransporter 2 (SGLT2) inhibitors (SGLT2) long term were shown to have less kidney function loss. A poster presented at Kidney ...

Nephrologists are initiating SGLT2 inhibitors earlier in the chronic kidney disease (CKD) treatment journey and continuing them well below labeled eGFR thresholds. At the same time, real-world uptake ...

SGLT2 inhibitors combat inflammation and slow kidney disease by elevating S-adenosylmethionine (SAM) levels, which suppress inflammatory gene activity through epigenetic modification. The benefits of ...

Two sodium glucose co-transporter 2 (SGLT2) inhibitors have beneficial effects in patients with type 2 diabetes regardless of baseline CV risk or renal function, according to two studies presented ...

Author: Deepak L. Bhatt, MD, MPH, MBA, Director of Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai ...

Treatment with an SGLT2 inhibitor may help patients with CKD or type 2 diabetes better preserve their kidney function. In the New England Journal of Medicine trial, investigators from The EMPA-KIDNEY ...

Credit: Thinkstock New review identifies benefits of sodium-glucose co-transporter-2 (SGLT2) inhibitors at almost all levels of kidney function. Sodium-glucose co-transporter-2 (SGLT2) inhibitors can ...

Please provide your email address to receive an email when new articles are posted on . SGLT2 inhibitors vs. other agents were tied to a slower eGFR decline for adults with ADPKD and type 2 diabetes.

SGLT2 inhibitors curb the action of a protein known as sodium-glucose cotransporter 2, which helps the kidneys reabsorb glucose from the blood. EMPACT-MI is the first analysis to determine if it is ...

SGLT2 inhibitors are linked to side effects such as genital infections, dehydration, and dizziness, which may increase the risk for falls in older adults. GLP-1 drugs often cause nausea and weight ...

Sodium/glucose cotransporter 2 (SGLT2; encoded by SLC5A2) inhibitors (also known as gliflozins) function to increase hepatic glucose production via induction of glucagon secretion in pancreatic α ...